Quality control of experimental autoimmune encephalomyelitis
Although multiple sclerosis (MS) is a uniquely human disease, nothing has influenced the thinking concerning the pathogenesis and treatment of MS quite as much as experimental autoimmune encephalomyelitis (EAE). EAE is a spectrum of neurological disorders that occurs in animals (including humans) following immune sensitization to central nervous system (CNS) antigens. Yet many decades on and, as reported by Vesterinen and colleagues in this issue, about 2000 compounds later it is a 'poor-show' that only three licensed, disease-modifying drugs, glatiramer acetate, mitoxantrone and natalizumab (beta interferon was used in MS before EAE testing), have been delivered from decades of research following pre-clinical studies in EAE. In this issue, Vesterinen and colleagues review and rate the quality of drug-treatment studies in the EAE. As the senior authors are clinicians rather than noted 'EAEologists', they have used meta-analysis and quality criteria that are perhaps more suited to clinical trials rather than animal studies. Nevertheless this paper does provide an 'outsiders' view of EAE and suggests that 'EAEologists' could do much better.
Meta-analysis of published trial data is often used to estimate the value of compounds or therapeutic strategies in the clinic. In humans there is a registry and duty to report negative as well as positive findings. In contrast negative or confirmation of positive data in animals studies rarely leave the editor's desk, a sad fact that could save scores of animals from repeated, futile experiments. This means that the published, experimental studies are clearly skewed with regard to efficacy. Linomide was the compound with the most consensus of activity in EAE based on repeated studies. 1 This appeared to have some potential for treatment of MS, but this failed because of an unfavourable side-effect profile. Side-effects are seldom an issue in animal studies that are usually of short duration and performed in pathogen-free environments. In contrast the therapeutic value of myelin and myelin proteins, which have been extensively investigated, was largely uninterpretable following meta-analysis, 1 yet their use can be the most effective treatment in EAE. 2 Therefore, such a simple, empirical approach to analyse the literature is, in our opinion, unlikely to indicate which agents could be effective in MS. Moreover, it is perhaps irrelevant, as this issue is generally based on the commercial interests of the pharmaceutical industry, long before any weightof evidence from published studies has been generated.
Vesterinen et al. 1 introduce the concept of 'quality' parameters based on pre-clinical stroke and clinical approaches and conclude that many EAE studies are, in their opinion, of 'poor quality' as judged by whether the studies adhered to the author's tick-box 'criteria of quality'. In a world of 'word-restricted manuscripts' many elements of methodology are often unreported. Therefore, the basic premise that undermines the report is that if the 'quality feature' was not mentioned it is recorded as not being performed. This is clearly not the case for many issues, particularly those for which it has only recently been in vogue to report. Furthermore, the markers of 'quality', i.e. blinding, randomization, power analysis, conflict of interest, and ethical review selected by Vesterinen et al. 1 may not rank as preferences to comment on. Nevertheless this report does point out the somewhat shocking omission of statistical and descriptive analysis in many EAE studies. Clearly the fault also lies with the reviewers of these papers who should pick up these issues.
Clinical trial studies can often be a relatively turgidread with little or no useful analysis or laboratory work underpinning putative disease mechanisms. Invariably these studies include tables of randomization, demographic details and side-effect profiles, yet these are seldom mentioned in EAE studies while the former are largely superfluous in animal studies that use relatively homogeneous, inbred animals maintained in controlled environments. Therefore, it is of interest and surprising that the lack of randomization leads to a marked bias to overestimate the efficacy of therapies. 1 In several studies, EAE susceptibility is influenced by gender and weight/age. Randomization bias should be simple to eliminate and report. Animals are easily randomized such as by paired allocations of similar starting outcomes or treatments within cages prior to experiments commencing. Importantly Vesterinen et al. 1 also suggest that bias can arise through not blinding the study. Blinding is important in human trials where 'placebo effects' can be as marked as the therapeutic activity of some drugs. Animals do not know if they are getting a drug while vehicles (placebos) are selected to be inert. However, observer bias apparently does occur 1 and is probably inevitable when dealing with visually assessed, subjective and non-linear clinical scoring systems as used in EAE. The daily analysis that is required to study EAE can be labour intensive and requires different experimenters to deliver agents and assess disease to effectively blind the study. Whilst this may not always be feasible due to resources, coding of test drugs, researcher-independent repetition and the use of supportive, objective outcome measures may help reduce bias of outcome effects. In the future, perhaps we will have a universally accepted, objective primary outcome measure (weight changes in animals in some instances can help). However, until then we may have to rely on trustworthy people and such inadequate, but well-defined, animal and human (such as the Expanded Disability Status Scale [EDSS]) motor outcome scales.
Another 'quality criteria' was the declaration of conflicts of interests. This phrase has become an important issue when discussing treatments that have financial consequences. Many clinicians have conflict lists to 'die for' while researchers seldom see non-academic reward or are not in science long enough to benefit from their discoveries. Therefore, one may feel that one has nothing to declare, because if you did you would surely declare it. However, as pressures increase for researchers to be academic entrepreneurs it is so easy to add four words 'conflicts of interest: none' to any manuscript. One can then let the editor/subeditors remove them for taking up unnecessary word space or incorporate this aspect into the submission process, which is the simple solution.
Likewise reporting animal welfare and ethical issues is also judged as an indicator of quality. Since the 1990s it has become popular to document accordance in manuscripts and indeed is a requirement of an increasing number of journals and funding agencies. While many papers (>70%) report adopting appropriate standards of animal welfare, 1 few papers mention 'environmental enrichment', e.g. chew toys or music or TVs that are frequently part of animal-husbandry practice. While this is not often reported it does not mean it is not used. This particular issue reflects a major problem of a tick-box analysis as used by Vesterinen et al. that assumes the 'worst' unless the 'best' is stated. While we should welcome and report the fact that our animal studies are independently supported as being of value, animal-welfare issues vary considerably from country to country. Many 'ethically reviewed' publications still report on injections into the footpads of animals to induce EAE, although this practise is banned in many countries since alternative methods are available that are as efficacious and do not require animals to walk on painfully, inflamed feet. Likewise, although it may make a pretty graph, it is questionable that animals are observed for hundreds of days, when the drug activity is clearly observed by 20-30 days. With common sense prevailing, unethical studies should be commented on and questioned and, where necessary, rejected by reviewers. Moreover, since there is no consensus on how EAE should be induced and assessed this has lead to many different scoring systems. 1 Each animal strain and inducing-antigen has unique characteristics that make a universal system of scoring impossible. Nevertheless, one should expect a minimum level of consistency of reporting, such as appropriate statistics, which appear to be lacking from so many EAE studies. 1 Another 'quality feature' was power analysis that was seldom cited in publications on EAE. 1 Despite this, some form of power calculation is often inherent in the ethical-review process although these power calculations are really geared to avoid false-negative studies, which published EAE studies seldom are. It is perhaps unsurprising therefore that they are not mentioned. However, it must be noted that group sizes for some published studies are much too small for the nonparametric statistics that should be, but are not always, applied to clinical scoring systems. The report by Vesterinen et al. 1 does provide power calculations for EAE studies and this should become a useful resource and a justification for large group sizes.
It is difficult to mistake paralysed tails or limbs of animals with EAE. This may explain why so many people use EAE as a paradigm to investigate autoimmune function rather than investigate other conditions that often utilize histological, hence single timepoint, outcomes. The study by Vesterinen et al. 1 makes no attempt to address the validity or purpose of the claims made from the EAE studies. Indeed many of the studies analysed are more concerned with investigation of immune-mechanism than finding a drug to treat MS. This may account for one of the more 'disturbing' statistics reported if one is looking for therapeutic efficacy. Over 70% of drug studies were initiated on or before disease induction, 1 which would currently never happen in a human context. EAE is one of the few experimental paradigms that can be relapsing and remitting, yet less than 1% of studies (drugs started after 3 weeks from induction) targeted this aspect of disease. In our experience the number of studies that initiate treatment with disease-modifying agents after a single relapse can probably be counted on one hand. We have demonstrated that animals with secondary progressive EAE, following relapsing EAE, do not respond to immunosuppressive strategies that otherwise completely eradicate relapses. 2 This is similar to observations in progressive MS. 3 Therefore many therapeutic compounds may have been doomed to failure, not because of the animal models, but because of the way information is translated into the clinic. EAE is not an isolated example of a disease model in which this has occurred. Studies in other experimental autoimmune paradigms have likewise failed to deliver a plethora of useful treatments. Whilst the cynical view would be to condemn all animal experimentation, it has given us numerous insights into fundamental biology, the pathological mechanisms underlying the diseases and drugs to treat people. Furthermore, animal models can only provide a sensible answer if one asks sensible questions of them. As it takes decades to move drugs from the bench to the bedside and we now know how to perform MS trials to detect drugs that stop relapses, let us hope that there is still time for some of the 1717 drugs, or those missed during the literature searches, to deliver useful treatments for MS. The paper by Vesterinen and colleagues is the first systematic approach to describe the characteristics of the EAE literature and is no doubt a starting point for comment rather than the last word. Only time will tell whether it will change laboratory protocols and reporting and, most importantly, the reviewing practises and the journal policies to submissions that can rapidly drive change. However, if you do not think about deficiencies in your own work, you will not be able to remove them.
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